Lost goodwill target (LGT) proteome

1/2

Pei ^{1) 2) 3)} reported a kind of proteome called lost goodwill target (LGT) proteome in the serum of the tumor patients which can reflect the different phase of tumor development or aggravation, which was also related to the patients' pathogenetic condition and mortality.

Ren et al. ⁴⁾ reported that the LGT proteome was produced under the pathologic condition of traumatic brain injury (TBI) patients, and the abundance of LGT proteome is closely associated with pathogenetic condition and prognosis of TBI patients; the LGT proteome may play an important role in predicting pathogenetic condition and prognosis of TBI patients.

Based on the findings above, LGT can also be found in severe TBI patients serum, and it may be the early warning sign for disease aggravation or even death. In order to investigate the clinical significance of LGT proteome, the study proceeded with surface enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS)^{5) 6)}.

Serum LGT proteome may be used as a promising marker for evaluating severity of severe TBI ⁷⁾.

Further research on LGT proteome is warranted to facilitate the prognostication and clinical decision making ⁸⁾.

1)

Y. Pei, S. Guo, Q. Wang, et al., "The first observation of the clinical significance of LGT proteome for cancer patients," Cancer Research and Clinic, vol. 17, no. 3, pp. 156–158, 2005.

P. Yi, S. Guo, Q. Wang, et al., "A newly discovered fingerprint of functional proteome," Zhongliu Yanjiu Yu Lingchuang, vol. 17, no. 3, pp. 153–155, 2005.

P. Yi, "Discovery and concluding of characteristics of prewarning proteome fingerprints which mark prognostic of malignant tumor," Shanxi Science and Technology Agency, vol. 193, p. 11, 2005.

J. R. Ren, G. L. Zhang, H. M. Ji, et al., "The clinical signifiance change of serumLGT proteome in patients with traumatic brain injury: a pilot study," Zhongguo Yaowu Yu Lingchuang, vol. 10, no. 10, pp. 1095–1097, 2010.

T. Gemoll, U. J. Roblick, G. Auer, H. Jörnvall, and J. K. Habermann, "SELDI-TOF serum proteomics and colorectal cancer: a current overview," Archives of Physiology and Biochemistry, vol. 116, no. 4-5, pp. 188–196, 2010.

V. Seibert, M. P. A. Ebert, and T. Buschmann, "Advances in clinical cancer proteomics: SELDI-ToF-mass spectrometry and biomarker discovery," Briefings in Functional Genomics and Proteomics, vol. 4, no. 1, pp. 16–26, 2005.

Ji H, Hu C, Zhang G, Ren J, Tan Y, Sun W, Wang J, Li J, Liu H, Xie R, Hao Z, Guo D. Determination of Serum Lost Goodwill Target Proteome in Patients with Severe Traumatic Brain Injury. Biomed Res Int. 2015;2015:183821. doi: 10.1155/2015/183821. Epub 2015 Sep 27. PubMed PMID: 26491659.

Ren JR, Ji HM, Ji JM, Feng JH, Zhang GL, Zhang HW. [The clinical significance of the relationship between serum lost goodwill target proteome and the acute physiology and chronic health evaluation II score of patient with critical illness]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2011 Mar;23(3):134-7. Chinese. PubMed PMID: 21366939. From: https://neurosurgerywiki.com/wiki/ - **Neurosurgery Wiki**

Permanent link: https://neurosurgerywiki.com/wiki/doku.php?id=lost_goodwill_target



Last update: 2024/06/07 02:56